The US Food and Drug Administration (FDA) on Wednesday sought comments on whether it should run a voluntary pilot program to evaluate the toxicology and quality of novel excipients.
While the agency does currently review new excipients as part of an investigational new drug application (IND) or a marketing application (NDA or BLA), FDA explains how certain novel excipients may provide public health benefits, such as improved drug delivery or utility in abuse-deterrent opioid formulations.
The term « excipient » is defined by FDA as any ingredient intentionally added to a drug or biologic that is not intended to have a therapeutic effect but may improve product delivery. Examples of excipients include fillers, extenders, diluents, wetting agents, solvents, emulsifiers, preservatives, flavors, absorption enhancers, sustained-release matrices and coloring agents.
As far as how the pilot would work, the agency notes: “FDA recognition of a novel excipient would mean that, based on a review of safety, manufacturing, and compositional information, FDA has determined that the proposed context of use (e.g., acute or chronic exposure by specified route(s) of administration up to specified amounts) is expected to be safe. This determination would obviate the need for FDA review of the excipient in the context of an IND if its use in the investigational product is consistent with the recognized context of use,” the agency explains…